Literature DB >> 6798719

Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide.

F Pisani, A Fazio, G Oteri, R Di Perri.   

Abstract

Diurnal variation in dipropylacetic acid (DPA) plasma levels was investigated in 47 and 42 epileptic patients, chronically treated with sodium dipropylacetate and dipropylacetamide (DPM), respectively, taken alone or in addition to other antiepilepic drugs. Fluctuation in DPA plasma levels was significantly less in patients receiving dipropylacetamide. The slow absorption and the more prolonged plasma half-life of dipropylacetamide accounted for these findings. Although the importance of diurnal fluctuations in DPA levels has not yet been established, possible clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798719     DOI: 10.1097/00007691-198103000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

1.  Valpromide inhibits human epoxide hydrolase.

Authors:  G M Pacifici; M Franchi; C Bencini; A Rane
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

2.  Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.

Authors:  M Bialer; A Haj-Yehia; N Barzaghi; F Pisani; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.

Authors:  K Badir; A Haj-Yehia; T B Vree; E van der Kleijn; M Bialer
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

4.  Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

5.  Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients.

Authors:  F Pisani; E Spina; C Trunfio; A Fazio; G Oteri; R Di Perri
Journal:  Ital J Neurol Sci       Date:  1983-06

6.  Mood stabilizers inhibit cytomegalovirus infection.

Authors:  Sara Ornaghi; John N Davis; Kelly L Gorres; George Miller; Michael J Paidas; Anthony N van den Pol
Journal:  Virology       Date:  2016-09-19       Impact factor: 3.616

Review 7.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18

8.  Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.

Authors:  M Bialer; A Rubinstein; I Raz; O Abramsky
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

10.  Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.

Authors:  G M Pacifici; A Temellini; L Giuliani; A Rane; H Thomas; F Oesch
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.